From: Systematic assessment of HER2/neu in gynecologic neoplasms, an institutional experience
Primary Site | Group I | Group II | Group III | Group IV | Group V | |||||
---|---|---|---|---|---|---|---|---|---|---|
CCCA | SCA | ENAdCA | MxSEAdCA | Other | ||||||
n | HER2+ | n | HER2+ | n | HER2+ | n | HER2+ | n | HER2+ | |
Endometrium | 6 | 2 (33.3 %) | 9 | 4 (44.4 %) | 22 | 11 | 1 (9.1 %) | 10 | 1 (10.0 %) | |
Ovary | 5 | 1 (20.0 %) | 30 | 1 (3.3 %) | 5 | 13 | 3 | |||
Fallopian Tube | 1 | 1 | ||||||||
Peritoneum | 5 | 1 | ||||||||
Pelvic Mass | 1 | 1 | ||||||||
Cervix | 1 | |||||||||
All Sites | 11 | 3 (27.3 %) | 45 | 5 (11.1 %) | 28 | 0 (0.0 %) | 26 | 1 (3.9 %) | 15 | 1 (6.7 %) |